Assenagon Asset Management
DYN icon

Assenagon Asset Management’s Dyne Therapeutics DYN Stock Holding History

Assenagon Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-286,644
Closed -$3.81M – 1394
2023
Q4 		$3.81M Sell
286,644
-434,830
-60% -$4.25M 0.01% 714
2023
Q3 		$6.46M Buy
721,474
+142,083
+25% +$1.53M 0.02% 509
2023
Q2 		$6.52M Buy
579,391
+540
+0.1% +$6.37K 0.02% 438
2023
Q1 		$6.67M Buy
578,851
+315,825
+120% +$4.1M 0.02% 495
2022
Q4 		$3.05M Hold
263,026
– – 0.01% 675
2022
Q3 		$3.34M Sell
263,026
-3,586
-1% -$41.1K 0.01% 575
2022
Q2 		$1.83M Sell
266,612
-28,617
-10% -$197K 0.01% 865
2022
Q1 		$2.85M Sell
295,229
-66,704
-18% -$568K 0.01% 701
2021
Q4 		$4.3M Buy
+361,933
New +$5.09M 0.01% 565

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Assenagon Asset Management's DYN Position: Q1 2024 in Review

Assenagon Asset Management sold out of Dyne Therapeutics (DYN) in Q1 2024, closing a stake of 286,644 shares — an estimated $3.81M sold.

Assenagon Asset Management first reported a position in DYN in Q4 2021 and held it in 9 quarters. The position peaked at $6.67M in Q1 2023. 169 funds tracked by Wall St. Rank hold DYN as of Q1 2024.

  • Assenagon Asset Management reported no remaining Dyne Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 286,644 Dyne Therapeutics shares in Q1 2024, an estimated $3.81M.
  • Assenagon Asset Management first reported a position in Dyne Therapeutics in Q4 2021 and held it in 9 quarters.
  • Assenagon Asset Management's Dyne Therapeutics position peaked at $6.67M in Q1 2023.
  • 169 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2024.

Based on Assenagon Asset Management's 13F filing for Q1 2024, filed 24 Apr 2024.